Armour Therapeutics is a biopharmaceutical company focused on the development of a new class of anti-hormone therapeutics for the treatment of reproductive tissue-based cancers. Armourís compounds are designed to maintain an anti-androgen effect in patients developing resistance to currently marketed anti-hormonals, with the additional benefit of blocking the relaxin hormone pathway, which in turn reduces tumour growth, impairs angiogenesis, constricts tumoral blood flow and reduces the risk for metastasis. Armour's anti-hormone therapy synergistically combines with certain marketed chemotherapeutics for increased efficacy and is being developed as both a monotherapy as well as a combination therapy for mid-stage to end-stage prostate cancer. Armourís lead compound, AT-001, developed at the University Health Network and Ontario Cancer Institute in Toronto, is a relaxin receptor antagonist for patients who develop hormone-refractory prostate cancer. Armour is also developing compounds for its AT-012 and AT-027 programs targeting breast and ovarian cancers, respectively.